Episodios

  • Could a new rescue inhaler strategy reduce severe asthma attacks in mild cases?
    May 28 2025
    This week's episode covers the effectiveness of a fixed-dose albuterol-budesonide combination for asthma, new findings on Nerodomelast for progressive pulmonary fibrosis, the FDA’s endorsement of a new COVID-19 vaccine targeting the JN.1 lineage, and insights into extended-phase anticoagulation for pediatric venous thromboembolism.
    Más Menos
    7 m
  • Could ending PEPFAR lead to 1 million new pediatric HIV cases by 2030?
    May 23 2025
    A Lancet study warns of consequences for HIV prevention if PEPFAR loses funding, potentially millions of new pediatric HIV cases and increased AIDS-related deaths. Medicare Part D is highlighted, with research linking subsidy loss to higher mortality rates. A report from BMJ notes a 3.1% decline in U.S. drug overdose deaths, signaling a possible peak in the fentanyl crisis.
    Más Menos
    5 m
  • Revisiting Anemia Response in Myelofibrosis: Revised International Working Group Criteria
    May 20 2025
    Drs. Pemmaraju and Bose discuss the revised International Working Group criteria for anemia response in patients with myelofibrosis, outlining new definitions for transfusion status, gender-specific hemoglobin thresholds, and benchmarks for major and minor responses.
    Más Menos
    7 m
  • Leukemic Transformation in Myelofibrosis: Risks, Realities, and Evolving Strategies
    May 19 2025
    Drs. Bose and Pemmaraju discuss leukemic transformation in patients with myelofibrosis, reviewing its incidence, as well as risk factors, treatment, and prognosis.
    Más Menos
    8 m
  • Understanding Secondary Myelofibrosis: Diagnosis, Treatment, and Prognosis
    May 16 2025
    Drs. Bose and Pemmaraju review secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia and how it differs from primary myelofibrosis that develops de novo.
    Más Menos
    6 m
  • How much did maternal RSV vaccines and nirsevimab lower infant hospitalizations?
    May 14 2025
    Maternal RSV vaccines and infant nirsevimab led to major drops in hospitalizations among infants ≤7 months, especially those ≤2 months old. The CDC’s 2025 nPEP guidelines stress starting HIV prevention within 72 hours of exposure, with rapid testing and follow-up care. Treatment should begin without delay, and patients at ongoing risk should transition to PrEP. Surgical site infections after colorectal surgery have increased 21% since 2019, highlighting the need to strengthen infection control.
    Más Menos
    5 m
  • Migraine Missteps: Common Diagnostic Pitfalls and How to Avoid Them
    May 9 2025
    Drs. Starling and VanderPluym discuss common diagnostic pitfalls in migraine medicine and how the misinterpretation of symptoms can lead to unnecessary testing or incorrect treatments.
    Más Menos
    13 m
  • Game Changer: Are CGRP Inhibitors the New First Line for Migraine Prevention?
    May 7 2025
    Drs. VanderPluym and Starling review the updated position statement from the American Headache Society indicating that CGRP-targeting migraine therapies should be considered as a first-line option.
    Más Menos
    12 m
adbl_web_global_use_to_activate_T1_webcro805_stickypopup